Clinical Trial Update: A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema [Phase 4]

View source ↗

Summary

Phase 4 trial of RYMPHYSIA for A1PI deficiency in adults with COPD-emphysema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• RYMPHYSIA

Snippet

Sponsor: Takeda | Conditions: Chronic Obstructive Pulmonary Disease (COPD), Alpha1-Antitrypsin Deficiency | Phase 4 | Status: WITHDRAWN